Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12458200 | 0.85 | APLNR (0.53) | APLNRCA2APEX1CYP2C19PIK3CD | |
| SCHEMBL22021481 | 0.84 | PIK3CA (0.46) | APLNRPIK3R1PIK3CACYP11B2CYP11B1 | |
| SCHEMBL22012108 | 0.82 | CYP11B2 (0.37) | APLNRPIK3R1PIK3CACYP11B2CYP11B1 | |
| SCHEMBL22778594 | 0.82 | APLNR (0.50) | APLNRCA2PTGS2APEX1CYP2C19 | |
| SCHEMBL21963211 | 0.80 | APLNR (0.35) | APLNRPIK3R1PIK3CACYP11B2CYP11B1 | |
| SCHEMBL22752315 | 0.79 | APLNR (0.47) | APLNRCA2PTGS2APEX1CYP2C19 | |
| SCHEMBL19475024 | 0.79 | APEX1 (0.45) | CA2PTGS2PTGS1APEX1CYP2C19 | |
| SCHEMBL30313919 | 0.78 | APLNR (0.53) | APLNRCA2PTGS2PTGS1 | |
| Hydrochloric Acid SCHEMBL29969521 | 0.76 | APLNR (0.52) | APLNRCA2PTGS2PTGS1 | |
| SCHEMBL11690551 | 0.76 | APLNR (0.71) | APLNRCA2APEX1CYP2C19PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | APLNR 1657/4885PIK3R1 3797/4885PIK3CA 3440/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | APLNR 1791/4885PIK3R1 3782/4885PIK3CA 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.